Viking Therapeutics (NASDAQ:VKTX) Trading Down 12.6% - What's Next?

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) shares were down 12.6% during trading on Monday . The stock traded as low as $29.20 and last traded at $29.76. Approximately 4,326,532 shares were traded during trading, a decline of 3% from the average daily volume of 4,447,204 shares. The stock had previously closed at $34.07.

Analyst Ratings Changes

Several equities research analysts have issued reports on VKTX shares. William Blair reiterated an "outperform" rating on shares of Viking Therapeutics in a research note on Wednesday, November 20th. Scotiabank initiated coverage on Viking Therapeutics in a report on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 price objective for the company. Piper Sandler dropped their price target on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a research report on Thursday, February 6th. Raymond James boosted their price objective on shares of Viking Therapeutics from $122.00 to $125.00 and gave the stock a "strong-buy" rating in a research note on Thursday, February 6th. Finally, Maxim Group lowered their price target on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $97.29.

Viking Therapeutics Price Performance

The business's fifty day moving average price is $36.28 and its 200 day moving average price is $52.07. The stock has a market cap of $3.37 billion, a P/E ratio of -30.20 and a beta of 0.90.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter last year, the company earned ($0.25) EPS. On average, analysts predict that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Marianna Mancini sold 54,215 shares of the business's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $2,317,691.25. Following the transaction, the chief operating officer now owns 374,134 shares in the company, valued at approximately $15,994,228.50. The trade was a 12.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Greg Zante sold 50,309 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $2,150,709.75. Following the sale, the chief financial officer now owns 165,259 shares of the company's stock, valued at approximately $7,064,822.25. This trade represents a 23.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 299,014 shares of company stock worth $12,782,849 in the last 90 days. Insiders own 4.70% of the company's stock.

Institutional Trading of Viking Therapeutics

Several hedge funds have recently modified their holdings of VKTX. United Advisor Group LLC bought a new position in shares of Viking Therapeutics during the 4th quarter worth about $234,000. Public Employees Retirement System of Ohio increased its holdings in shares of Viking Therapeutics by 5.1% during the fourth quarter. Public Employees Retirement System of Ohio now owns 47,547 shares of the biotechnology company's stock valued at $1,913,000 after acquiring an additional 2,295 shares in the last quarter. Mpwm Advisory Solutions LLC acquired a new position in shares of Viking Therapeutics during the fourth quarter worth approximately $170,000. Waverly Advisors LLC lifted its holdings in shares of Viking Therapeutics by 34.6% in the 4th quarter. Waverly Advisors LLC now owns 48,369 shares of the biotechnology company's stock worth $1,946,000 after purchasing an additional 12,426 shares in the last quarter. Finally, Woodline Partners LP grew its position in Viking Therapeutics by 46.2% in the 4th quarter. Woodline Partners LP now owns 93,294 shares of the biotechnology company's stock valued at $3,754,000 after purchasing an additional 29,475 shares during the period. Institutional investors own 76.03% of the company's stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.